MEDICATION OVERUSE HEADACHE: PRACTICAL GUIDELINES
https://doi.org/10.21518/2079-701X-2018-1-26-32
Abstract
Medication overuse headache (MOH) is defined as a secondary/symptomatic headache when HA occurs on 15 or more days per month, when the therapeutic agent is used excessively for three or more months. MOH is often combined with chronic forms of primary HA (chronic migraine and chronic tension headache). About 1% of the population periodically receives about 10 tablets of various analgesics per month. Due to high prevalence, high social and economic costs, high rates of recurrence, MOH represents a significant problem for both the health care system and practitioners. The review discusses issues of epidemiology, mechanisms of formation, diagnostic criteria and the most effective approaches to the treatment of MOH.
About the Authors
A. V. Sergeev
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University), Kozhevnikov Clinic for Nervous Diseases
Russian Federation
PhD in medicine
Russian Federation
PhD in medicine
V. A. Parfenov
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University), Kozhevnikov Clinic for Nervous Diseases
Russian Federation
MD, Prof
Russian Federation
MD, Prof
References
1. Bigal ME, Rapoport AM, Sheftell FD et al. Transformed migraine and medication overuse in a tertiary headache centre–clinical characteristics and treatment outcomes. Cephalalgia, 2004, 24: 483.
2. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol, 2004, 3: 475.
3. Табеева Г.Р., Чечет Е.А. Лекарственно-индуцированная головная боль. Эпидемиология, диагностика, лечение. Медицинский совет, 2015, 17: 62-67.
4. Steiner TJ, Stovner LJ, Katsarava Z et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain, 2014, 15: 31.
5. Айзенберг И.В, Кацарава З. Хроническая абу-зусная головная боль. Российский журнал «Боль», 2005, 1(6): 57-65.
6. Куцемелов И.Б., Табеева Г.Р. Эпидемиология первичной головной боли (по данным популяционного исследования взрослого населения г. Ростова-на-Дону). Журнал «Боль», 2004, 4(5): 25–31.
7. Diener HC, Dahlof CG. Headache associated with chronic use of substances. In: The Headaches, Second ed, Olesen J, Tfelt-Hansen P, Welch KM (Eds), Lippincott, Williams & Wilkins, Philadelphia 1999. p. 871.
8. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia, 2013, 33: 629.
9. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache, 2008, 48: 1157-1168.
10. Limmroth V, Katsarava Z, Fritsche G et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology, 2002, 59: 1011-1014.
11. Katsarava Z, Fritsche G, Muessig M et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology, 2001, 57: 1694–1698.
12. Lance F, Parkes C, Wilkinson M. Does analgesic abuse cause headaches de novo? Headache, 1988, 28: 61.
13. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache, 2003, 43: 179.
14. Cargnin S, Viana M, Ghiotto N, Bianchi M, Sances G, Tassorelli C, Nappi G, Canonico PL, Genazzani AA, Terrazzino S. Functional polymorphisms in COMT and SLC6A4 genes influence the prognosis of patients with medication overuse headache after withdrawal therapy. Eur J Neurol, 2014 Jul, 21(7): 989-95.
15. Sergeev A, Mesherina M., Tabeeva G. Predictive factors for the relapse medication overuse headache. A prospective study. The Journal of Headache and Pain, 2013, 14(Suppl 1): 173.
16. Sergeev A, Azimova J, Klimov E, Skorobogatykh K, Kokaeva Z, Kondratieva N, Kochetkova T, Tabeeva G. Positive association between -1021C/T polymorphism of dopamine-b-hydroxylase gene and level substance dependence in medication-overuse headache. The Journal of Headache and Pain, 2014, 15(Suppl 1): B33.
17. Meng EI, Dodick D, Ossipov M, Porreca F. Pathophysiology of medication overuse headache: Insights and hypotheses from preclinical studies. Cephalalgia, 2011, 31(7): 851-60.
18. Supornsilpchai W, Supang MG, Srikiatkhachorn A. Involvement of pro-nociceptive 5-HT2A receptor in the pathogenesis of medication-overuse headache. Headache, 2010, 50: 185-197.
19. Mesherina MI, Tabeeva GR, Sergeev AV, Оsipova VV. Visual evoked potentials during withdrawal period in patients with medication overuse headache. Abstract of 15th International Headache Congress. Berlin, 2011.
20. Saper JR, Hamel RL, Lake AE 3rd. Medication overuse headache (MOH) is a biobehavioural disorder. Cephalalgia, 2005, 25: 545.
21. Zwart JA, Dyb G, Hagen K et al. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology, 2003, 61: 160.
22. Сергеев А.В., Мещерина М.И., Табеева Г.Р. Головная боль, связанная с избыточным приемом анальгетиков: клинико-психологический и нейрофизиологический анализ, особенности периодам отмены. Эпилепсия и пароксизмальные состояния, 2011, 3(3): 21-28.
23. Golovacheva V, Parfenov V, Tabeeva G, Osipova V. Combined cognitive-behavioral and pharmacological therapies for chronic migraine and chronic TTH: are treatment response different? Cephalalgia, 2015, 35(6S): 33.
24. Grazzi L, Andrasik F, D’Amico D, Usai S, Kass S, Bussone G. Disability in chronic migraine patients with medication overuse: Treatment effects at 1 year follow-up. Headache, 2004, 44: 678–683.
25. Evers S, Jensen R, European Federation of Neurological Societies. Treatment of medication overuse headache-guideline of the EFNS headache panel. Eur J Neurol, 2011, 18: 1115.
26. Katsarava Z, Fritsche G, Muessig M et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology, 2001, 57: 1694.
27. Freitag FG, Lake A 3rd, Lipton R et al. Inpatient treatment of headache: an evidence-based assessment. Headache, 2004, 44: 342.
28. Pringsheim T, Becker WJ. Triptans for symptomatic treatment of migraine headache. BMJ, 2014, 348: g2285.
29. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol, 2004, 55: 19.
30. Hagen K, Albretsen C, Vilming ST et al. Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia, 2009, 29: 221.
31. Hagen K, Stovner LJ. A randomized controlled trial on medication-overuse headache: outcome after 1 and 4 years. Acta Neurol Scand. Suppl, 2011, 32: 38.
32. Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: A systematic review. Cephalalgia, 2016, 36: 371.
Review
For citations:
Sergeev AV, Parfenov VA. MEDICATION OVERUSE HEADACHE: PRACTICAL GUIDELINES. Meditsinskiy sovet = Medical Council. 2018;(1):26-32. (In Russ.) https://doi.org/10.21518/2079-701X-2018-1-26-32
Views:
781
Email this article 